Maxim Group began coverage on shares of BioNano Genomics (NASDAQ:BNGO) in a research report released on Monday morning, TipRanks reports. The firm issued a buy rating and a $2.00 target price on the stock.
Several other research analysts also recently weighed in on BNGO. Zacks Investment Research downgraded BioNano Genomics from a hold rating to a sell rating in a research note on Tuesday, July 7th. Oppenheimer reiterated a buy rating and set a $1.50 price target on shares of BioNano Genomics in a research note on Thursday, June 11th. Finally, Roth Capital reiterated a buy rating and set a $1.00 price target on shares of BioNano Genomics in a research note on Thursday, June 4th.
Shares of NASDAQ:BNGO opened at $0.68 on Monday. The company has a market capitalization of $60.27 million, a PE ratio of -0.36 and a beta of 1.88. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.26 and a quick ratio of 1.10. The business has a fifty day moving average price of $0.69 and a two-hundred day moving average price of $0.61. BioNano Genomics has a 1 year low of $0.25 and a 1 year high of $4.70.
BioNano Genomics (NASDAQ:BNGO) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). BioNano Genomics had a negative return on equity of 15,217.90% and a negative net margin of 390.52%. Sell-side analysts anticipate that BioNano Genomics will post -0.41 earnings per share for the current year.
A hedge fund recently raised its stake in BioNano Genomics stock. UBS Group AG raised its holdings in BioNano Genomics Inc (NASDAQ:BNGO) by 284.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 198,799 shares of the company’s stock after acquiring an additional 147,151 shares during the period. UBS Group AG owned approximately 0.24% of BioNano Genomics worth $101,000 at the end of the most recent reporting period. 2.07% of the stock is currently owned by institutional investors.
BioNano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Story: Why do companies issue monthly dividends?
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.